View allCompanies IntelligenceNuvectis Pharma IncSRC IncView all
The study is designed to explore the drug candidate’s clinical activity as a potential treatment for platinum-resistant, ARID1a-mutated ovarian carcinoma.
NuvectisNuvectis has already received fast track designation for the NXP800 development programme.
It is also developing another drug candidate, NXP900, a new small molecule inhibitor targeting the SRC/YES1 kinases.
The FDA has cleared the IND for NXP900 and a Phase Ia dose escalation trial is yet to commence.
“This orphan drug designation is an important milestone in our journey toward our mission of developing NXP800 for the treatment of serious conditions of unmet medical need in oncology.”